Table 2.

Phase II and phase III clinical trials of irreversible multitargeted HER family TKIs in NSCLC

^aPatients are exempt from prior chemotherapy if they have a confirmed EGFR mutation or had ≥6 months of benefit from erlotinib or gefitinib.

^bPatients with HER-2 mutations may have prior therapy.

Abbreviations: EGFR, epidermal growth factor receptor; FISH, fluorescence in situ hybridization; HER, human epidermal growth factor receptor; NSCLC, non-small cell lung cancer; TKI, tyrosine kinase inhibitor.